Abstract
The 21-amino acid peptide endothelin-1 (ET-1) is the predominant isoform of the endothelin peptide family, which includes ET-2, and ET-3. These peptides display a variety of physiological activities including vasoconstriction and the stimulation of cell proliferation in tissues both within and outside of the cardiovascular system. They exert their actions via activation of two distinct receptor subtypes, ETA and ETB, belonging to the G protein-coupled receptor (GPCR) superfamily. Ligands of these receptors have received numerous citations in the recent pharmaceutical literature. In particular receptor antagonists, both ETA- and ETB-selective, as well as non-selective, have been described due to their wide therapeutic potential. As a part of our program toward the development of selective ETA ligands we have designed and we now report new molecules based on 2-substituted-4-aryl-3-quinolinecarboxylic acid moiety. Binding profile for some compounds (40, 44, 46, and 47) of this class showed a reasonable affinity and selectivity for ETA receptors.
Keywords: 2-Substituted-4-aryl-3-quinolinecarboxylic acids derivatives, endothelin receptors, G protein-coupled receptors, hypertension
Medicinal Chemistry
Title: Synthesis and Endothelin Receptor Binding Affinity of a Novel Class of 2-Substituted-4-aryl-3-quinolinecarboxylic Acid Derivatives
Volume: 4 Issue: 2
Author(s): Valeria Pittala, Maria Modica, Loredana Salerno, Maria Angela Siracusa, Francesco Guerrera, Ilario Mereghetti, Alfredo Cagnotto, Tiziana Mennini and Giuseppe Romeo
Affiliation:
Keywords: 2-Substituted-4-aryl-3-quinolinecarboxylic acids derivatives, endothelin receptors, G protein-coupled receptors, hypertension
Abstract: The 21-amino acid peptide endothelin-1 (ET-1) is the predominant isoform of the endothelin peptide family, which includes ET-2, and ET-3. These peptides display a variety of physiological activities including vasoconstriction and the stimulation of cell proliferation in tissues both within and outside of the cardiovascular system. They exert their actions via activation of two distinct receptor subtypes, ETA and ETB, belonging to the G protein-coupled receptor (GPCR) superfamily. Ligands of these receptors have received numerous citations in the recent pharmaceutical literature. In particular receptor antagonists, both ETA- and ETB-selective, as well as non-selective, have been described due to their wide therapeutic potential. As a part of our program toward the development of selective ETA ligands we have designed and we now report new molecules based on 2-substituted-4-aryl-3-quinolinecarboxylic acid moiety. Binding profile for some compounds (40, 44, 46, and 47) of this class showed a reasonable affinity and selectivity for ETA receptors.
Export Options
About this article
Cite this article as:
Pittala Valeria, Modica Maria, Salerno Loredana, Siracusa Angela Maria, Guerrera Francesco, Mereghetti Ilario, Cagnotto Alfredo, Mennini Tiziana and Romeo Giuseppe, Synthesis and Endothelin Receptor Binding Affinity of a Novel Class of 2-Substituted-4-aryl-3-quinolinecarboxylic Acid Derivatives, Medicinal Chemistry 2008; 4 (2) . https://dx.doi.org/10.2174/157340608783789095
DOI https://dx.doi.org/10.2174/157340608783789095 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advancement in the Treatment of Cardiovascular Diseases: Conventional Therapy to Nanotechnology
Current Pharmaceutical Design Diagnosis and Management of Heart Failure with Preserved Ejection Fraction: 10 Key Lessons
Current Cardiology Reviews Characterizing the Binding of Angiotensin Converting Enzyme I Inhibitory Peptide to Human Hemoglobin: Influence of Electromagnetic Fields
Protein & Peptide Letters Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?
Current Drug Targets Percutaneous Treatment of Hydatid Liver Cyst
Recent Patents on Anti-Infective Drug Discovery Brain MRI, Apoliprotein E Genotype, and Plasma Homocysteine in American Indian Alzheimer Disease Patients and Indian Controls
Current Alzheimer Research Interplay between RNA Methylation Eraser <i>FTO</i> and Writer <i>METTL3</i> in Renal Clear Cell Carcinoma Patient Survival
Recent Patents on Anti-Cancer Drug Discovery Cognitive Function and the Ageing Process: The Peculiar Role of Mild Thyroid Failure
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Neuroprotection by Alpha 2-Adrenergic Agonists in Cerebral Ischemia
Current Neuropharmacology Biochemical, Hematological and Histopathological Indices of Wistar Rats Fed Vitamin and Mineral Deficient Diets Supplemented with Moringa oleifera Leaf Meal
Current Nutrition & Food Science Biomarkers for Systemic Therapy in Ovarian Cancer
Current Cancer Drug Targets One-Pot Three-Component Synthesis and Molecular Docking of Some Novel 2-Thiazolyl Pyridines as Potent Antimicrobial Agents
Mini-Reviews in Medicinal Chemistry Schizophrenia and Liver Dysfunction Caused by Portacaval Shunting
Current Psychiatry Reviews Patent Selections
Recent Patents on Cardiovascular Drug Discovery Urocortins: Take Them to Heart
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Targeting Mitochondria for Cardiac Protection
Current Drug Targets Do Rheumatoid Arthritis Patients Rate their Health Status Different than their Caregivers?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Metabolic Treatment of Patients with Coronary Artery Disease: Effects on Quality of Life and Effort Angina
Current Pharmaceutical Design Cardiovascular Risk Factors and Dietary Patterns
Current Nutrition & Food Science Triple Threat: The Na+/Ca2+ Exchanger in the Pathophysiology of Cardiac Arrhythmia, Ischemia and Heart Failure
Current Drug Targets